Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Taguchi

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|June 24, 2015
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first studyNoriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, et al.
Oncology Reports|September 27, 2016
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First studyMaki Hagihara, Noriyoshi Iriyama, Chikashi Yoshida, et al.
Leukemia & Lymphoma|June 9, 2016
Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemiaEtsuko Yamazaki, Heiwa Kanamori, Megumi Itabashi, et al.
Blood|October 27, 2012
Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experienceHidehiro Itonaga, Hideki Tsushima, Jun Taguchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in JapanChika Kawajiri-Manako, Emiko Sakaida, Chikako Ohwada, et al.
Hematological Oncology|January 11, 2020
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experienceHikaru Sakamoto, Hidehiro Itonaga, Yasushi Sawayama, et al.
Blood|November 26, 2010
A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
Leukemia Research|February 7, 2018
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first studyYuho Najima, Chikashi Yoshida, Noriyoshi Iriyama, et al.
Radiation Oncology Journal|March 29, 2024
Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapyYusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, et al.
Hematological Oncology|September 2, 2018
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantationKoji Kato, Naokuni Uike, Atsushi Wake, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|June 24, 2015
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first studyNoriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, et al.
Oncology Reports|September 27, 2016
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First studyMaki Hagihara, Noriyoshi Iriyama, Chikashi Yoshida, et al.
Leukemia & Lymphoma|June 9, 2016
Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemiaEtsuko Yamazaki, Heiwa Kanamori, Megumi Itabashi, et al.
Blood|October 27, 2012
Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experienceHidehiro Itonaga, Hideki Tsushima, Jun Taguchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 8, 2018
Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in JapanChika Kawajiri-Manako, Emiko Sakaida, Chikako Ohwada, et al.
Hematological Oncology|January 11, 2020
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experienceHikaru Sakamoto, Hidehiro Itonaga, Yasushi Sawayama, et al.
Blood|November 26, 2010
A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remissionSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
Leukemia Research|February 7, 2018
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first studyYuho Najima, Chikashi Yoshida, Noriyoshi Iriyama, et al.
Radiation Oncology Journal|March 29, 2024
Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapyYusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, et al.
Hematological Oncology|September 2, 2018
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantationKoji Kato, Naokuni Uike, Atsushi Wake, et al.
Pageof 16